[Anti-atherosclerotic effect].
Takai
Shinji
S
Department of Pharmacology, Osaka Medical College.
Miyazaki
Mizuo
M
D000450:Aldosterone / Q000494:pharmacology / Q000502:physiology*; D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D011945:Receptors, Angiotensin / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D011945:Receptors, Angiotensin; D000804:Angiotensin II; D000450:Aldosterone